There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neumora Therapeutics, Inc. (NMRA – Research Report) and Amylyx Pharmaceuticals Inc (AMLX – Research Report) with bullish sentiments.
Neumora Therapeutics, Inc. (NMRA)
Needham analyst Ami Fadia maintained a Buy rating on Neumora Therapeutics, Inc. today and set a price target of $23.00. The company’s shares closed last Thursday at $16.96.
According to TipRanks.com, Fadia is a 4-star analyst with an average return of
Currently, the analyst consensus on Neumora Therapeutics, Inc. is a Strong Buy with an average price target of $26.00, a 54.8% upside from current levels. In a report issued on October 11, Stifel Nicolaus also maintained a Buy rating on the stock with a $26.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Amylyx Pharmaceuticals Inc (AMLX)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $8.00. The company’s shares closed last Thursday at $3.92, close to its 52-week low of $1.58.
According to TipRanks.com, Fein is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Amylyx Pharmaceuticals Inc with a $4.67 average price target.
Read More on NMRA: